Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS)
CNY 21.63
(-0.18%)
CNY 21.63
(-0.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 424.7 Million CNY | 125.73% |
| 2022 | 168.16 Million CNY | 144.02% |
| 2021 | 62.14 Million CNY | 153.59% |
| 2020 | -97.33 Million CNY | -132.06% |
| 2019 | 356.82 Million CNY | -39.73% |
| 2018 | 531.47 Million CNY | -12.55% |
| 2017 | 517.5 Million CNY | 51.15% |
| 2016 | 381.1 Million CNY | -11.71% |
| 2015 | 431.63 Million CNY | 33.55% |
| 2014 | 323.19 Million CNY | -18.54% |
| 2013 | 396.75 Million CNY | 51.11% |
| 2012 | 261.91 Million CNY | 20.04% |
| 2011 | 218 Million CNY | 30.89% |
| 2010 | 166.59 Million CNY | 39.36% |
| 2009 | 120.25 Million CNY | 62.86% |
| 2008 | 73.44 Million CNY | 126.15% |
| 2007 | 29.96 Million CNY | 291.14% |
| 2006 | 7.82 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 95.22 Million CNY | -17.0% |
| 2024 Q2 | 69.2 Million CNY | -40.38% |
| 2024 Q3 | 106.66 Million CNY | 31.44% |
| 2023 Q1 | 26.1 Million CNY | -33.31% |
| 2023 Q3 | 71.88 Million CNY | 33.88% |
| 2023 FY | - CNY | 125.73% |
| 2023 Q4 | 74.68 Million CNY | 3.9% |
| 2023 Q2 | 53.69 Million CNY | 105.7% |
| 2022 FY | - CNY | 144.02% |
| 2022 Q4 | 39.14 Million CNY | 384.22% |
| 2022 Q3 | 8.08 Million CNY | 139.81% |
| 2022 Q2 | -20.3 Million CNY | 7.95% |
| 2022 Q1 | -22.05 Million CNY | -262.95% |
| 2021 Q3 | -63.96 Million CNY | -276.66% |
| 2021 Q2 | 36.2 Million CNY | 152.42% |
| 2021 Q1 | -69.07 Million CNY | 60.58% |
| 2021 FY | - CNY | 153.59% |
| 2021 Q4 | 13.53 Million CNY | 121.16% |
| 2020 Q2 | 31.77 Million CNY | 123.71% |
| 2020 Q3 | 13.08 Million CNY | -58.82% |
| 2020 Q4 | -175.24 Million CNY | -1439.35% |
| 2020 FY | - CNY | -132.06% |
| 2020 Q1 | -134.03 Million CNY | -170.89% |
| 2019 Q2 | 78.82 Million CNY | 176.03% |
| 2019 FY | - CNY | -39.73% |
| 2019 Q4 | 189.06 Million CNY | 3953.74% |
| 2019 Q3 | 4.66 Million CNY | -94.08% |
| 2019 Q1 | -103.67 Million CNY | 0.0% |
| 2018 FY | - CNY | -12.55% |
| 2017 FY | - CNY | 51.15% |
| 2016 FY | - CNY | -11.71% |
| 2015 FY | - CNY | 33.55% |
| 2014 FY | - CNY | -18.54% |
| 2013 Q1 | 56.95 Million CNY | 88.39% |
| 2013 Q2 | 74.59 Million CNY | 30.96% |
| 2013 Q3 | 73.65 Million CNY | -1.26% |
| 2013 FY | - CNY | 51.11% |
| 2012 Q2 | 44.35 Million CNY | -35.04% |
| 2012 FY | - CNY | 20.04% |
| 2012 Q4 | 30.23 Million CNY | -61.11% |
| 2012 Q3 | 77.74 Million CNY | 75.3% |
| 2012 Q1 | 68.28 Million CNY | 80.14% |
| 2011 Q2 | 50.13 Million CNY | 41.64% |
| 2011 Q4 | 37.9 Million CNY | -35.94% |
| 2011 Q1 | 35.39 Million CNY | -17.89% |
| 2011 FY | - CNY | 30.89% |
| 2011 Q3 | 59.17 Million CNY | 18.02% |
| 2010 Q1 | 21.56 Million CNY | 0.0% |
| 2010 Q2 | 35.29 Million CNY | 63.67% |
| 2010 Q4 | 43.11 Million CNY | -1.43% |
| 2010 FY | - CNY | 39.36% |
| 2010 Q3 | 43.73 Million CNY | 23.9% |
| 2009 FY | - CNY | 62.86% |
| 2008 FY | - CNY | 126.15% |
| 2007 FY | - CNY | 291.14% |
| 2006 FY | - CNY | 0.0% |